Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149958 (
complex partial seizures
)
2,563
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Intracerebroventricular (i.c.v.) administration of
NPY
inhibits limbic seizure activity induced by kainic acid or electrical hippocampal stimulation in vivo. Similarly, antiepileptiform effects have been demonstrated in hippocampal slice models. This suggests a possible antiepileptic potential of NPYergic agonists in future treatment of
complex partial seizures
in humans. To further characterize the antiepileptic potential of
NPY
, the effects of
NPY
administered i.c.v. were studied on seizures induced by subcutaneous injection of pentylenetetrazole (PTZ), a widely used antiepileptic screening test believed to model generalized myoclonic seizures.
NPY
significantly and dose-dependently inhibited PTZ-induced clonic seizures as revealed by increases in seizure latencies. In addition,
NPY
caused an overall significant reduction in the number of rats developing tonic seizures and in mortality following PTZ, indicating that
NPY
also reduces seizure severity. By demonstrating antiepileptic activity of
NPY
in yet another seizure model, this study further adds to the concept of
NPY
receptors as potentially novel targets in future treatment of seizure disorders. Specifically, antiepileptic effects in the PTZ model suggest that NPYergic agonists might also prove active against human myoclonic seizures.
...
PMID:Antiepileptic effects of NPY on pentylenetetrazole seizures. 980 20
